Immuneering (NASDAQ:IMRX) Given “Buy” Rating at Chardan Capital

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $20.00 target price on the stock. Chardan Capital’s price objective would suggest a potential upside of 309.00% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a report on Friday, March 27th. Wall Street Zen upgraded Immuneering from a “sell” rating to a “hold” rating in a research note on Sunday, April 19th. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Immuneering in a research note on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Immuneering Price Performance

Immuneering stock traded up $0.02 during trading hours on Tuesday, reaching $4.89. The stock had a trading volume of 696,152 shares, compared to its average volume of 1,323,706. The company has a market cap of $316.37 million, a price-to-earnings ratio of -4.18 and a beta of 0.37. The business’s 50 day moving average price is $5.34 and its 200-day moving average price is $5.69. Immuneering has a 52 week low of $1.40 and a 52 week high of $10.08.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09. On average, sell-side analysts forecast that Immuneering will post -1.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Immuneering

A number of large investors have recently bought and sold shares of IMRX. Jane Street Group LLC purchased a new stake in Immuneering in the first quarter valued at approximately $32,000. Geode Capital Management LLC raised its stake in shares of Immuneering by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after buying an additional 4,458 shares during the period. XTX Topco Ltd acquired a new position in shares of Immuneering during the 2nd quarter worth approximately $90,000. Bridgeway Capital Management LLC raised its stake in shares of Immuneering by 57.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock worth $322,000 after buying an additional 35,000 shares during the period. Finally, Corient Private Wealth LLC acquired a new position in Immuneering in the 2nd quarter valued at $215,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.